Press Releases

Press Releases

Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Date: 11.06.2024

Read Post

Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Date: 05.28.2024

Read Post

Affini-T Therapeutics to Present Data from Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Date: 05.01.2024

Read Post

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024

Date: 04.07.2024

Read Post

Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting

Date: 03.13.2024

Read Post

Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Date: 01.07.2024

Read Post

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Date: 11.13.2023

Read Post

Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Date: 10.31.2023

Read Post

Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer

Date: 06.02.2023

Read Post

Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Date: 05.25.2023

Read Post

Affini-T Therapeutics to Present Novel CRISPR Gene Editing Data from its Oncogenic Driver Program Targeting KRAS at the American Society of Gene and Cell Therapy 26th Annual Meeting

Date: 05.09.2023

Read Post

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023

Date: 04.13.2023

Read Post

Affini-T Therapeutics Announces Licensing Agreement with Leading Comprehensive Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs

Date: 04.13.2023

Read Post

Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023

Date: 04.06.2023

Read Post

Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS

Date: 03.03.2023

Read Post

Affini-T Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Date: 01.05.2023

Read Post

ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

Date: 11.15.2022

Read Post

Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Date: 11.07.2022

Read Post

Affini-T Therapeutics Named to the 2022 Endpoints 11

Date: 09.22.2022

Read Post

Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer

Date: 07.26.2022

Read Post

Affini-T Therapeutics Appoints Jill DeSimone to its Board of Directors

Date: 07.11.2022

Read Post

Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients

Date: 06.15.2022

Read Post

Affini-T Therapeutics to Present at Upcoming Investor and Industry Conferences

Date: 06.08.2022

Read Post

Clinical Strategy for Enhancing Affini-T Therapeutics’ Merkel Polyoma Virus TCR Therapy to be Presented at ASCO 2022

Date: 06.02.2022

Read Post

Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy

Date: 05.03.2022

Read Post

Affini-T Expands Board of Directors with Appointments of Michael Varney, Ph.D., and Daniel Faga

Date: 04.05.2022

Read Post

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Date: 03.22.2022

Read Post

Affini-T Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference